Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
GLORIA-AF Registry Program - Second and Third Phases
NCT01468701 · View on ClinicalTrials.gov ↗
Study Summary
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Conditions Studied
Study Locations (20)
California
- Diagnamics, Inc — Encinitas
- Allianz Medical and Research Center — Fountain Valley
- B&K Medical Research Center — Fresno
- American Clinical Trials — Hawaiian Gardens
- Scripps Clinic — La Jolla
- La Mesa Cardiac Center — La Mesa
- Los Alamitos Cardiovascular — Los Alamitos
- VA Greater Los Angeles Healthcare System — Los Angeles
Arkansas
- Sparks Regional Medical Center — Fort Smith
- Dr. Michael A. Frais, Cardiologist, P.A. — Hot Springs
- Cardiology and Medicine Clinic — Little Rock
- Donald W. Reynolds Institute on Aging — Little Rock
- Arkansas Cardiology, PA — Little Rock
Alabama
- University South Alabama Medical Center — Mobile
- Black Warrior Research — Northport
- Scottsboro Quick Care Clinic — Scottsboro
Arizona
- Phoenix Heart PLLC — Glendale
- Mercy Cinic Hot Springs Communities — Hot Springs
- Midwest Internal Medicine, PLLC — Lake Havasu City
Alaska
- Alaska Heart Institute — Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,235 participants |
| Start Date | 2011-11-07 |
| Est. Completion | 2020-01-10 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468701
The ClinicalTrials.gov registry entry for NCT01468701 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 37,235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01468701 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Arkansas, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01468701 about?
NCT01468701 is a clinical study titled "GLORIA-AF Registry Program - Second and Third Phases". In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160....
What is the current status of trial NCT01468701?
This trial is currently completed. The enrollment target is 37,235 participants. The study started on 2011-11-07. Estimated completion is 2020-01-10.
What conditions does trial NCT01468701 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01468701?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01468701 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.